荨麻疹

20 0 138 71　咪唑斯汀治疗慢性特发性荨麻疹临床研究/吴国勤 (复旦大学附属中山医院皮肤科 )…∥临床皮肤科杂志 .- 2 0 0 1,30 (3) .- 181～ 183为评价咪唑斯汀治疗慢性荨麻疹的疗效和安全性 ,采用随机开放平行对照的方法 ,将 6 0例慢性荨麻疹患者分成两组 ,分别接受咪唑斯汀或氯雷他定治疗 ,疗程 2 8天。结果表明咪唑斯汀能有效缓解患者的瘙痒症状 ,减少风团数目与直径 ,治疗有效率为 93.10 % ;氯雷他定为 87.1% ,经检验差别无显著性 (P>0 .0 5 )。表 2参 6　 (余春艳 )2 0 0 13872　斯特林治疗慢性荨麻疹疗效观察 /林益钱(温州市疾病预…     

补气祛风方联合咪唑斯汀治疗慢性特发性荨麻疹60例疗效观察

目的:观察补气祛风方联合咪唑斯汀治疗慢性特发性荨麻疹的临床疗效。方法:将130例慢性特发性荨麻疹患者随机分为3组。补气祛风方组37例,给予补气祛风方治疗;咪唑斯汀组33例,给予咪唑斯汀治疗;联合治疗组60例,给予补气祛风方与咪唑斯汀治疗。3组疗程均为4周。结果:慢性特发性荨麻疹症状缓解有效率补气祛风方组为75.67%,咪唑斯汀组为69.69%,联合治疗组为93.33%。联合治疗组分别与补气祛风方组、咪唑斯汀组比较,差异均有统计学意义(P<0.05)。结论:补气祛风方联合咪唑斯汀治疗慢性特发性荨麻疹,可以提高临床疗效。     

雷公藤多苷联合咪唑斯汀治疗慢性特发性荨麻疹22例疗效观察

目的:探讨雷公藤多苷对自体血清皮肤试验(autologous serum skin test,ASST)阳性的慢性特发性荨麻疹(chronic idiopathic urticaria,CIU)的疗效。方法:对185例CIU患者采用自体血清皮肤试验,将ASST阳性的43例患者随机分为两组,治疗组服用雷公藤多苷和咪唑斯汀,对照组服用咪唑斯汀,记录临床症状评分及病史,治疗后第4周再次进行ASST。结果:治疗组痊愈率为33.3%,对照组为5.26%;有效率两组分别为71.4%和36.8%,两者差异均有统计学意义(P<0.05)。第4周两组ASST的血清风团及组胺风团直径小于治疗前直径,药物有明显的抑制作用(P<0.05)。两组对ASST的血清风团及组胺风团的影响程度差异无统计学意义(P>0.05)。结论:雷公藤多苷能有效治疗ASST阳性的慢性特发性荨麻疹,安全性好。     

咪唑斯汀治疗慢性荨麻疹42例疗效观察

目的：探讨咪唑斯汀治疗慢性荨麻疹的疗效与安全性。方法：42例慢性荨麻疹患者采用咪唑斯汀10mg，每日1次，连续服用14天。结果：基本治愈19例，显效13例，有效6例，无效4例，总有效率为76．2％。结论：咪唑斯汀治疗慢性荨麻疹疗效确切，安全性好。     

3种抗组胺药治疗慢性特发性荨麻疹的临床研究

目的:评价第2代抗组胺药咪唑斯汀、西替利嗪、氯雷他定治疗慢性特发性荨麻疹的疗效和安全性。方法:采用随机开放平行对照的方法,对96例慢性特发性荨麻疹患者进行随机分组,分别予以咪唑斯汀10mg、西替利嗪10mg、氯雷他定10mg,均每日1次口服,观察治疗第14天、第28天的临床疗效及停药1周后的复发率。结果:三者治疗慢性特发性荨麻疹第14天和第28天的有效率分别为:咪唑斯汀组90.0%和96.7%,西替利嗪组85.3%和94.2%,氯雷他定组90.6%和93.8%,三者之间差异无显著性(P>0.05)。停药1周后的复发率,咪唑斯汀组为40.0%,西替利嗪组为35.3%,氯雷他定组为28.1%。整个试验过程中均无明显严重不良反应出现。结论:咪唑斯汀、西替利嗪和氯雷他定治疗慢性特发性荨麻疹临床疗效好,安全性高,在改善临床症状及控制复发方面各有所长。     

咪唑斯汀(皿治林)治疗120例慢性荨麻疹临床观察

目的　观察咪唑斯汀治疗慢性荨麻疹的疗效及安全性。方法　慢性荨麻疹患者 12 0例予咪唑斯汀 10mg ,1次 /d共 2周口服。 结果　治疗 2周有效率为 92 .6%。结论　咪唑斯汀口服治疗慢性荨麻疹简便、有效、安全。     

卡介菌多糖核酸联合咪唑斯汀治疗慢性特发性荨麻疹疗效观察

目的观察卡介菌多糖核酸联合咪唑斯汀治疗慢性特发性荨麻疹的疗效。方法146例患者随机分成两组,治疗组采用卡介菌多糖核酸注射液肌注0.5 mg,隔日1次,同时咪唑斯汀片口服10 mg,1次/d,连续治疗4周;对照组单独口服咪唑斯汀,方法疗程同治疗组。结果治疗组有效率为92.1%,对照组为74.3%。两组比较差异有显著性(χ2=8.42,P<0.01)。结论卡介菌多糖核酸联合咪唑斯汀治疗慢性特发性荨麻疹疗效确切。     

咪唑斯汀治疗慢性特发性荨麻疹临床观察

目的：探讨咪唑斯汀缓释片治疗慢性特发性荨麻疹（CIU）的临床疗效及安全性。方法：72例CIU患者口服咪唑斯汀缓释片10mg，每日1次，连续28天。采用症状和体征总积分评估疗效。结果：72例CIU患者治疗后第28天的痊愈率和总有效率分别为72．22％和91．66％。结论：咪唑斯汀缓释片治疗CIU是安全有效的。     

咪唑斯汀治疗慢性荨麻疹217例临床观察

目的　观察咪唑斯汀治疗慢性荨麻疹的疗效及安全性。方法　对 2 17例慢性荨麻疹患者口服咪唑斯汀2周进行临床观察。结果　咪唑斯汀治疗 2 17例慢性荨麻疹的有效率在第 7天和第 14天分别为 5 5 .3 %和 94.5 % ,治疗过程中不良反应仅为 5 .5 % ,且症状轻。结论　咪唑斯汀治疗慢性荨麻疹安全方便、疗效确实。     

咪唑斯汀治疗慢性荨麻疹临床疗效观察

目的：评价咪唑斯汀治疗慢性荨麻疹的有效性及安全性。方法：对145例慢性荨麻疹患者应用咪唑斯汀（皿治林）10mg，每晚1次口服，治疗2周。结果：治疗后患者的症状总积分明显低于治疗前，痊愈率为70．3％，总有效率为90．3％，且无明显不良反应。结论：使用咪唑斯汀治疗慢性荨麻疹是安全有效的。     

Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab

In recent years, a series of new drugs have been developed through the application of molecular biology. These drugs act by blocking specific molecules of the immune system and have been developed to act on specific targets that play an important role in the pathophysiology of the diseases in which their therapeutic use has now been approved. Over time, experience has been accumulated in the use of these drugs in the treatment of skin diseases for which they have not been approved but in which the pathophysiology suggests that they could also be effective. The use of these drugs is increasing in difficult-to-treat cases of skin diseases for which the drugs are not approved. The second part of this review of off-label use of biologic agents in dermatology considers the use of etanercept, efalizumab, alefacept, rituximab, basiliximab, omalizumab, and cetuximab.     

Treatment of Paracoccidioidomycosis, Candidiasis, Chromomycosis, Lobomycosis, and Mycetoma with Ketoconazole

ABSTRACT: The authors present the use of ketoconazole in 27 cases of paracoccidioidomycosis, eight of mycetoma, seven of chromomycosis. four of systemic candidiasis and one of lobomycosis. The drug was administered orally in a dosage of 200 to 400 mg per day within a period of up to 90 days. The results of the treatment for paracoccidioidomycosis were of cicatrization of the cutaneous lesions in three to four weeks in 24 patients and in two, from six to seven weeks. Out of 27 patients, 14 presented pulmonary lesions. The evolution within a 90-day period showed radiological cure in one case, improvement in seven, and unaltered picture in five patients. In one there was no further control. In the three out of four cases of candidiasis there was clinical and mycological cure and in one case marked improvement. In seven cases of chromomycosis there was marked improvement in two moderate in four, and slight in one case. There was slight improvement in one case of lobomycosis, and in eight cases of mycetoma moderate improvement in three, slight in three and none in two, but the mycological examinations wore still positive. The drug tolerance was excellent.     

Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up

Vitiligo is an acquired pigmentary disorder of unknown etiology that is clinically characterized by the development of white macules related to the selective loss of melanocytes. The prevalence of the disease is around 1% in the United States and in Europe, but ranges from less than 0.1% to greater than 8% worldwide. A recorded predominance of women may reflect their greater willingness to express concern about cosmetically relevant issues. Half of all patients develop the disease before 20 years of age. Onset at an advanced age occurs but is unusual, and should raise concerns about associated diseases, such as thyroid dysfunction, rheumatoid arthritis, diabetes mellitus, and alopecia areata. Generalized vitiligo is the most common clinical presentation and often involves the face and acral regions. The course of the disease is unpredictable and the response to treatment varies. Depigmentation may be the source of severe psychological distress, diminished quality of life, and increased risk of psychiatric morbidity. Part I of this two-part series describes the clinical presentation, histopathologic findings, and various hypotheses for the pathogenesis of vitiligo based on past and current research.     

Association of auxotypes of Neisseria gonorrhoeae and susceptibility to penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, and moxalactam

Isolates of Neisseria gonorrhoeae from 304 patients attending a venereal disease clinic were examined by a plate dilution method for their susceptibility to six antibiotics: penicillin G, spectinomycin, tetracycline, cefaclor, cefoxitin, and moxalactam. The isolates were also characterized by gonococcal auxotyping. The most frequent auxotypes were Nonrequiring, 58%; Pro-, 14%; Pro- Arg (Orn*) Ura-, 14%; Arg- Hyx- Ura-, 6%; and a miscellaneous group consisting of 8% of the isolates. If the entire group of isolates were examined, moxalactam was the most active of the antibiotics; 94% of the isolates were inhibited by less than or equal to 0.25 microgram/ml. The Pro- Arg (Orn*) Ura- isolates were relatively resistant to penicillin G and cefoxitin. The Arg- Hyx- Ura- group of isolates was the most susceptible of the auxotypes to all of the antibiotics except spectinomycin. The uncommon auxotype Arg (Orn*) Ura- has a requirement for arginine that is satisfied by citrulline but not by ornithine. The results of the present study indicate that the nutritional requirements of gonococci may be associated with their response to certain antibiotics.